Cargando…

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

INTRODUCTION: Intensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In patients with insulin-treated type 2 diabetes, the addition of glucagon-like peptide-1 recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dejgaard, Thomas Fremming, Knop, Filip Krag, Tarnow, Lise, Frandsen, Christian Seerup, Hansen, Tanja Stenbæk, Almdal, Thomas, Holst, Jens Juul, Madsbad, Sten, Andersen, Henrik Ullits
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390685/ https://www.ncbi.nlm.nih.gov/pubmed/25838513 http://dx.doi.org/10.1136/bmjopen-2015-007791

Ejemplares similares

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
por: Hansen, Christian Stevns, et al.
Publicado: (2019)

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018)

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2019)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials
por: Dejgaard, Thomas F., et al.
Publicado: (2021)

A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats
por: Zhang, Qian, et al.
Publicado: (2019)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
por: Madsbad, Sten
Publicado: (2015)

SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Berman, Casey, et al.
Publicado: (2023)

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials
por: Storgaard, Heidi, et al.
Publicado: (2014)

Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
por: Asmar, Ali, et al.
Publicado: (2017)

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
por: Colin, Ides M, et al.
Publicado: (2023)

Postprandial Insulin Secretion After Gastric Bypass Surgery: The Role of Glucagon-Like Peptide 1
por: Holst, Jens Juul
Publicado: (2011)

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
por: Kumarathurai, Preman, et al.
Publicado: (2016)

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
por: Courrèges, J-P, et al.
Publicado: (2008)

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials
por: Hansen, Morten, et al.
Publicado: (2012)

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
por: Zobel, Emilie H, et al.
Publicado: (2021)

Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials
por: Kähler, Pernille, et al.
Publicado: (2014)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption
por: Kårhus, Martin Lund, et al.
Publicado: (2021)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion
por: Douglas Galsgaard, Katrine, et al.
Publicado: (2023)

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
por: Garber, Alan J.
Publicado: (2011)

Chenodeoxycholic acid stimulates glucagon‐like peptide‐1 secretion in patients after Roux‐en‐Y gastric bypass
por: Nielsen, Signe, et al.
Publicado: (2017)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines
por: Warrer, Pernille, et al.
Publicado: (2015)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
por: Harris, Stewart, et al.
Publicado: (2020)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i17mt2fppuuour95bngfq72d0n